Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dravet syndrome
Biotech
Stoke's Dravet syndrome med released of partial clinical hold
Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program.
Annalee Armstrong
Aug 7, 2024 8:54am
Takeda takes $140M loss on failed epilepsy drug, touts FDA run
Jul 31, 2024 9:14am
Takeda flunks pivotal epilepsy tests but mulls path to market
Jun 17, 2024 8:50am
Stoke's shares up 90% as epilepsy drug cuts convulsive seizures
Mar 26, 2024 9:09am
Longboard’s shares triple as epilepsy med halves seizure rates
Jan 2, 2024 10:49am
Ovid sells some royalty rights to Takeda-partnered seizure drug
Oct 18, 2023 8:00am
